NYSE:VOR Vor Biopharma (VOR) Stock Price, News & Analysis $0.96 +0.01 (+1.05%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.95▼$1.0150-Day Range$0.91▼$1.7452-Week Range$0.90▼$3.18Volume194,515 shsAverage Volume477,008 shsMarket Capitalization$65.67 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get Vor Biopharma alerts: Email Address Vor Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,199.4% Upside$12.50 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$20,357 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.49) to ($1.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.53 out of 5 starsMedical Sector519th out of 936 stocks 3.5 Analyst's Opinion Consensus RatingVor Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVor Biopharma has only been the subject of 3 research reports in the past 90 days.Read more about Vor Biopharma's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for VOR. Previous Next 0.0 Dividend Strength Dividend YieldVor Biopharma does not currently pay a dividend.Dividend GrowthVor Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VOR. Previous Next 3.0 News and Social Media Coverage News SentimentVor Biopharma has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.Search InterestOnly 5 people have searched for VOR on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows3 people have added Vor Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vor Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,357.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Vor Biopharma is held by insiders.Percentage Held by Institutions97.29% of the stock of Vor Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vor Biopharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vor Biopharma are expected to grow in the coming year, from ($1.49) to ($1.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vor Biopharma is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vor Biopharma is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Vor Biopharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Vor Biopharma Stock (NYSE:VOR)Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More VOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VOR Stock News HeadlinesJuly 9, 2024 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 4, 2024 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 28, 2024 | finanznachrichten.deBio-Thera Solutions, Ltd: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UKMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vor Biopharma Amid Promising Clinical Trials and Market Potential ExpansionMay 14, 2024 | markets.businessinsider.comBuy Rating Affirmed: Vor Biopharma’s Clinical and Financial FortitudeMay 11, 2024 | markets.businessinsider.comSilvan Tuerkcan Reaffirms Buy Rating for Vor Biopharma Citing Clinical Progress and Expanding Market PotentialMay 10, 2024 | markets.businessinsider.comPromising Clinical Trials and Stable Financial Outlook Bolster Buy Rating for Vor BiopharmaJuly 27, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 9, 2024 | msn.comVOR Stock Earnings: Vor Biopharma Beats EPS for Q1 2024May 9, 2024 | globenewswire.comVor Bio Reports First Quarter 2024 Financial Results and Provides Company UpdateMay 6, 2024 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesMay 3, 2024 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | globenewswire.comVor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of DirectorsApril 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vor Biopharma on Clinical Progress and Market PotentialApril 1, 2024 | globenewswire.comVor Bio to Participate in Upcoming Investor ConferencesMarch 29, 2024 | finance.yahoo.comHere's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn SituationMarch 28, 2024 | investorplace.comThe Penny Stock A-List: 7 High-Profile Companies on the Verge of GreatnessSee More Headlines Receive VOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vor Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry N/A Sub-IndustryPharmaceutical Products Current SymbolNYSE:VOR CUSIPN/A CIK1817229 Webwww.vorbiopharma.com Phone617-655-6580FaxN/AEmployees140Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$17.50 Low Stock Price Target$10.00 Potential Upside/Downside+1,199.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares68,260,000Free Float65,052,000Market Cap$65.67 million OptionableNot Optionable Beta-0.34 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Robert Ang M.B.A. (Age 49)M.D., MBBS, President, CEO & Director Comp: $943.91kDr. Tirtha Chakraborty Ph.D. (Age 51)Chief Scientific Officer Comp: $661.98kDr. Eyal C. Attar M.D. (Age 53)Chief Medical Officer Comp: $660.55kDr. Siddhartha Mukherjee DPHIL (Age 53)M.D., Ph.D., Scientific Founder & Chairman of Scientific Advisory Board Dr. Nathan D. Jorgensen M.B.A. (Age 47)Ph.D., Chief Financial Officer Comp: $608.48kMs. Tania Philipp (Age 52)Chief People Officer Mr. John C. King M.B.A. (Age 48)Chief Commercial Officer Mr. Samir Vattompadam M.S.Senior Vice President of Portfolio Strategy & Program ManagementMr. David Phillips M.B.A.Senior VP & Head of QualityMore ExecutivesKey CompetitorsZevra TherapeuticsNASDAQ:ZVRAImmutepNASDAQ:IMMPMersana TherapeuticsNASDAQ:MRSNGossamer BioNASDAQ:GOSSCorMedixNASDAQ:CRMDView All CompetitorsInsiders & InstitutionsEyal C AttarSold 14,645 sharesTotal: $20,356.55 ($1.39/share)Artal Group S.A.Sold 1,347,424 shares on 5/17/2024Ownership: 1.465%Vanguard Group Inc.Bought 69,436 shares on 5/10/2024Ownership: 2.657%Acadian Asset Management LLCBought 53,708 shares on 5/10/2024Ownership: 0.079%SG Americas Securities LLCSold 8,114 shares on 5/7/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions VOR Stock Analysis - Frequently Asked Questions How have VOR shares performed this year? Vor Biopharma's stock was trading at $2.25 on January 1st, 2024. Since then, VOR stock has decreased by 57.2% and is now trading at $0.9620. View the best growth stocks for 2024 here. How were Vor Biopharma's earnings last quarter? Vor Biopharma Inc. (NYSE:VOR) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.37) by $0.08. When did Vor Biopharma IPO? Vor Biopharma (VOR) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Evercore ISI, Barclays and Stifel served as the underwriters for the IPO. How do I buy shares of Vor Biopharma? Shares of VOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:VOR) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vor Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
